Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 37, 2007 - Issue 1
186
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Pharmacokinetic study of darbepoetin alfa: Absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats

, , , , , & show all
Pages 74-90 | Received 03 Aug 2006, Accepted 02 Sep 2006, Published online: 22 Sep 2008

References

  • Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Seminars in Oncology 1992; 19(3 Suppl. 8)29–35
  • Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, Heatherington AC, Maroni BJ. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology and Therapy 2002; 72: 546–555
  • Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrology and Dialysis Transplantation 2004; 19: 1224–1230
  • Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer 2001; 84(Suppl. 1)3–10
  • Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoetin. Experimental Hematology 2003; 31: 290–299
  • Elliott SG, Lorenzini T, Strickland T, Delorme E, Egrie JC. Rational design of novel erythropoiesis stimulating protein (ARANESP): A super-sialated molecule with increased biological activity [abstract]. Blood 2000; 96: 82
  • Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine 1987; 316: 73–78
  • Eschbach JW, Haley NR, Adamson JW. The use of recombinant erythropoietin in the treatment of the anemia of chronic renal failure. Annals of the New York Academy of Sciences 1989b; 554: 225–230
  • Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. New England Journal of Medicine 1989a; 321: 158–163
  • Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, Buzzoni R, Bajetta E. Treatment of cancer-related anemia with epoetin alfa: A review. Cancer Treatment Review 2004; 30: 563–575
  • Gavaret JM, Deme D, Nunez J, Salvatore G. Sequential reactivity of tyrosyl residues of thyroglobulin upon iodination catalyzed by thyroid peroxidase. Journal of Biology and Chemistry 1977; 252: 3281–3285
  • Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. British Journal of Cancer 2001; 84(Suppl. 1)17–23
  • Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O’Byrne J, Rossi G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer 2002; 87: 268–276
  • Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 2002; 16(10 Suppl. 11)23–29
  • Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist 2004; 9: 97–107
  • Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. American Journal of Health System Pharmacology 2005; 62: 54–62
  • Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrology and Dialysis Transplantation 2003; 18: 362–369
  • MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Journal of the American Society of Nephrology 1999; 10: 2392–2395
  • Misaizu T, Shinkai H, Hirosawa T, Kaneko T. Metabolic fate of KRN5702: Plasma level, distribution, metabolism and excretion of KRN5702 after a single subcutaneous administration to rats. Xenobiotic Metabolism and Disposition 1993; 8: 73–91
  • Nunez J, Pommier J. Formation of thyroid hormones. Vitamins and Hormones 1982; 39: 175–229
  • Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004; 9: 451–458
  • Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G. A randomized comparison of every 2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004; 9: 696–707
  • Smith Jr RE, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, Brosman S, Bukowski R, Murdock M, Rarick M, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. British Journal of Cancer 2001; 84(Suppl. 1)24–30
  • Uemura I, Niwa T, Nagao N, Misaizu T, Shinkai H. Metabolic fate of recombinant human erythropoietin (II)-plasma level, distribution, metabolism and excretion of 125I-KRN(5702) after single intravenous administration to rats. Clinical Report 1988; 22: 415–434

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.